サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1339168

筋弛緩薬市場、シェア、規模、動向、産業分析レポート：薬物タイプ別、投与経路別、流通チャネル別、地域別、およびセグメント別予測、2023-2032年

Muscle Relaxant Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs); By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023-2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 117 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
筋弛緩薬市場、シェア、規模、動向、産業分析レポート：薬物タイプ別、投与経路別、流通チャネル別、地域別、およびセグメント別予測、2023-2032年
出版日: 2023年07月23日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の筋弛緩剤市場規模は2032年までに56億7,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

筋弛緩薬とその利点に関する認知度の高まり、ドラッグデリバリー技術の進歩も市場成長の原動力になると予想されます。また、治療レジメンの一部として筋弛緩薬を含む併用療法の使用が増加していることも、今後数年間の市場成長を促進すると予想されます。さらに、筋弛緩剤のジェネリック医薬品が低価格で入手できるようになったことも、特に新興国において市場成長の原動力になると予想されます。

仕事に関連した筋骨格系障害はヘルスケア従事者の間でよく見られる問題であり、腰痛は最も頻繁に報告される苦情の一つです。このため、これらの症状を管理し、罹患者の生活の質を向上させるために、筋弛緩薬などの効果的な治療法の必要性が浮き彫りになっています。その結果、このような薬剤の需要は増加し、市場に成長機会をもたらす可能性があります。

FDA承認薬以外にも、ベンゾジアゼピン、ガバペンチノイド、オピオイドなど、痙縮や筋痙攣に適応外で使用される筋弛緩薬があります。しかし、これらの薬剤は副作用のリスクが高く、乱用の可能性もあるため、これらの症状への使用は推奨されていないです。ヘルスケア専門家は、各薬剤のリスクとベネフィットを慎重に評価し、個々の患者のニーズに合わせた治療を行うことが重要です。

副作用は、筋弛緩薬の使用に伴う重大な懸念事項です。眠気、めまい、錯乱、口の渇き、目のかすみなどです。これらの副作用は重篤で、場合によっては生命を脅かすことさえあり、業界の成長を制限しかねないです。したがって、これらの薬剤の利点と潜在的なリスクのバランスをとり、ケースバイケースで慎重に使用を評価することが極めて重要です。

筋弛緩薬市場レポートハイライト

骨格弛緩薬セグメントは、筋骨格系疾患の増加や併用療法の革新により、最大のシェアを占めました。

経口剤セグメントは、処方率の高さ、経口剤製品の入手可能性により、市場シェアが大きいです。

ホスピタリティ分野は、熟練した医師や看護師の存在、効果的な治療オプションにより、より大きな売上シェアを占めると予測されます。

北米は専用のヘルスケア・インフラが存在するため、調査期間中の成長が期待されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の筋弛緩薬市場に関する洞察

  • 筋弛緩薬市場- 流通チャネルのスナップショット
  • 筋弛緩薬市場力学
    • 促進要因と機会
      • 高齢者人口の増加
      • 筋骨格系疾患の有病率の増加
    • 抑制要因と課題
      • 筋弛緩剤の副作用
  • PESTEL分析
  • 筋弛緩薬市場流通チャネルの動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の筋弛緩薬市場、薬剤の種類別

  • 主な調査結果
  • イントロダクション
  • 骨格筋弛緩薬
  • 顔面筋弛緩薬
  • 神経筋遮断薬

第6章 世界の筋弛緩薬市場、投与経路別

  • 主な調査結果
  • イントロダクション
  • オーラル
  • 注射可能

第7章 世界の筋弛緩薬市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 診断研究所

第8章 世界の筋弛緩薬市場、地域別

  • 主な調査結果
  • イントロダクション
    • 筋弛緩薬市場評価、地域別、2019-2032年
  • 筋弛緩薬市場-北米
    • 北米：筋弛緩薬市場、薬剤タイプ別、2019-2032年
    • 北米：筋弛緩薬市場、流通チャネル別、2019-2032年
    • 北米：筋弛緩薬市場、投与経路別、2019-2032年
    • 筋弛緩薬市場-米国
    • 筋弛緩薬市場- カナダ
  • 筋弛緩薬市場- 欧州
    • 欧州：筋弛緩薬市場、薬剤タイプ別、2019-2032年
    • 欧州：筋弛緩薬市場、流通チャネル別、2019-2032
    • 欧州：筋弛緩薬市場、投与経路別、2019-2032年
    • 筋弛緩薬市場- 英国
    • 筋弛緩薬市場- フランス
    • 筋弛緩薬市場- ドイツ
    • 筋弛緩薬市場- イタリア
    • 筋弛緩薬市場- スペイン
    • 筋弛緩薬市場- オランダ
    • 筋弛緩薬市場- ロシア
  • 筋弛緩薬市場- アジア太平洋
    • アジア太平洋地域：筋弛緩薬市場、薬剤タイプ別、2019～2032年
    • アジア太平洋：筋弛緩薬市場、流通チャネル別、2019-2032年
    • アジア太平洋地域：筋弛緩薬市場、投与経路別、2019～2032年
    • 筋弛緩薬市場- 中国
    • 筋弛緩薬市場- インド
    • 筋弛緩薬市場- マレーシア
    • 筋弛緩薬市場- 日本
    • 筋弛緩薬市場- インドネシア
    • 筋弛緩薬市場- 韓国
  • 筋弛緩薬市場-中東およびアフリカ
    • 中東およびアフリカ：筋弛緩薬市場、薬剤タイプ別、2019～2032年
    • 中東およびアフリカ：筋弛緩薬市場、流通チャネル別、2019-2032年
    • 中東およびアフリカ：筋弛緩薬市場、投与経路別、2019-2032年
    • 筋弛緩薬市場- サウジアラビア
    • 筋弛緩薬市場- アラブ首長国連邦
    • 筋弛緩薬市場- イスラエル
    • 筋弛緩薬市場- 南アフリカ
  • 筋弛緩薬市場-ラテンアメリカ
    • ラテンアメリカ：筋弛緩薬市場、薬剤タイプ別、2019-2032年
    • ラテンアメリカ：筋弛緩薬市場、流通チャネル別、2019-2032
    • ラテンアメリカ：筋弛緩薬市場、投与経路別、2019-2032年
    • 筋弛緩薬市場- メキシコ
    • 筋弛緩薬市場- ブラジル
    • 筋弛緩薬市場- アルゼンチン

第9章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Amneal Pharmaceuticals
  • Ipsen Biopharmaceuticals
  • Merz Pharmaceuticals
  • Par Pharmaceutical
  • Endo Pharmaceuticals
  • Vertical Pharmaceuticals
  • Mallinckrodt
  • SteriMax
  • Eisai Co.
  • Metacel Pharmaceuticals
  • Metacel Pharmaceuticals
図表

List of Tables

  • Table 1 Global Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 2 Global Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 3 Global Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Muscle Relaxant Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 6 North America: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 7 North America: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 10 U.S.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 13 Canada: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 16 Europe: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 18 UK: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 19 UK: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 21 France: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 22 France: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 25 Germany: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 28 Italy: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 31 Spain: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 37 Russia: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 42 China: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 43 China: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 45 India: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 46 India: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 52 Japan: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 58 South Korea: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 67 UAE: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 70 Israel: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 73 South Africa: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 76 Latin America: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 79 Mexico: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 82 Brazil: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 85 Argentina: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Muscle Relaxant Drugs Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Route of Administration
  • Figure 7. Global Muscle Relaxant Drugs Market, by Route of Administration, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Type
  • Figure 9. Global Muscle Relaxant Drugs Market, by Drug Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Muscle Relaxant Drugs Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Muscle Relaxant Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Muscle Relaxant Drugs Market
目次
Product Code: PM3548

The global muscle relaxant drugs market size is expected to reach USD 5.67 billion by 2032, according to a new study by Polaris Market Research. The report "Muscle Relaxant Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Skeletal Muscle Relaxant Drugs, Facial Muscle Relaxant Drugs); By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Growing awareness about muscle relaxant drugs and their benefits, along with advancements in drug delivery technologies, are also expected to drive market growth. The increasing use of combination therapies that include muscle relaxants as a part of the treatment regimen is also expected to propel market growth in the coming years. Furthermore, the availability of generic versions of muscle relaxants at lower prices is expected to drive market growth, particularly in emerging economies.

Work-related musculoskeletal disorders are a common issue among healthcare workers, and lower back pain is one of the most frequently reported complaints. This highlights the need for effective treatments, such as muscle relaxant drugs, to manage these conditions and improve the quality of life for affected individuals. As a result, the demand for such drugs is likely to increase, which could provide growth opportunities for the market.

In addition to the FDA-approved drugs, there are also other muscle relaxant medications used off-label for spasticity or muscle spasms, including benzodiazepines, gabapentinoids, and opioids. However, their use for these conditions is not recommended as they have a higher risk of adverse effects and abuse potential. It is important for healthcare professionals to carefully evaluate the risks and benefits of each medication and tailor the treatment to the individual patient's needs.

Side effects are a significant concern associated with the use of muscle relaxants. It includes drowsiness, dizziness, confusion, dry mouth, and blurred vision. These side effects can be severe and, in some cases, even life-threatening, which can limit the growth of the industry. Therefore, it is crucial to balance the benefits of these drugs against the potential risks and carefully evaluate their use on a case-by-case basis.

Muscle Relaxant Drugs Market Report Highlights

Skeletal relaxant segment held the largest share, owing to rise in musculo-skeletal disorders, and innovation in combination therapies.

Oral segment accounted for the larger market share owing to their high prescription rate, and availability in products in oral form

Hospital segment is projected to experience larger revenue share, due to the presence skilled doctors and nurses, and effective treatment options

North America is expected to grow over the study period, due to presence of dedicated healthcare infrastructure

The global players include: Amneal Pharmaceuticals, Ipsen Biopharmaceuticals, Merz Pharmaceuticals, Par Pharmaceutical, Endo Pharmaceuticals, Vertical Pharmaceuticals, Mallinckrodt, SteriMax, Eisai Co., Metacel Pharmaceuticals, and Teva Pharmaceuticals.

Polaris Market Research has segmented the muscle relaxant drugs market report based on drug type, route of administration, distribution channel, and region:

Muscle Relaxant Drugs, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Skeletal Muscle Relaxant Drugs
  • Facial Muscle Relaxant Drugs
  • Neuromuscular Blocking Agents

Muscle Relaxant Drugs, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oral
  • Injectable

Muscle Relaxant Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Diagnostic Labs

Muscle Relaxant Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Distribution Channels
    • 3.2.1. Primary Distribution Channels
    • 3.2.2. Secondary Distribution Channels

4. Global Muscle Relaxant Drugs Market Insights

  • 4.1. Muscle Relaxant Drugs Market - Distribution Channel Snapshot
  • 4.2. Muscle Relaxant Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing geriatric population
      • 4.2.1.2. Increasing prevalence of musculoskeletal disorders
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Adverse effects of muscle relaxants
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Muscle Relaxant Drugs Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Muscle Relaxant Drugs Market, by Drug Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
  • 5.3. Skeletal Muscle Relaxant Drugs
    • 5.3.1. Global Muscle Relaxant Drugs Market, by Skeletal Muscle Relaxant Drugs, by Region, 2019-2032 (USD Billion)
  • 5.4. Facial Muscle Relaxant Drugs
    • 5.4.1. Global Muscle Relaxant Drugs Market, by Facial Muscle Relaxant Drugs, by Region, 2019-2032 (USD Billion)
  • 5.5. Neuromuscular Blocking Agents
    • 5.5.1. Global Muscle Relaxant Drugs Market, by Neuromuscular Blocking Agents, by Region, 2019-2032 (USD Billion)

6. Global Muscle Relaxant Drugs Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 6.3. Oral
    • 6.3.1. Global Muscle Relaxant Drugs Market, by Oral, by Region, 2019-2032 (USD Billion)
  • 6.4. Injectable
    • 6.4.1. Global Muscle Relaxant Drugs Market, by Injectable, by Region, 2019-2032 (USD Billion)

7. Global Muscle Relaxant Drugs Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Hospital Pharmacy
    • 7.3.1. Global Muscle Relaxant Drugs Market, by Hospital Pharmacy, By Region, 2019-2032 (USD Billion)
  • 7.4. Retail Pharmacy
    • 7.4.1. Global Muscle Relaxant Drugs Market, by Retail Pharmacy, By Region, 2019-2032 (USD Billion)
  • 7.5. Online Pharmacy
    • 7.5.1. Global Muscle Relaxant Drugs Market, by Online Pharmacy, By Region, 2019-2032 (USD Billion)
  • 7.6. Diagnostic Labs
    • 7.6.1. Global Muscle Relaxant Drugs Market, by Diagnostic Labs, By Region, 2019-2032 (USD Billion)

8. Global Muscle Relaxant Drugs Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Muscle Relaxant Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Muscle Relaxant Drugs Market - North America
    • 8.3.1. North America: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.3.4. Muscle Relaxant Drugs Market - U.S.
      • 8.3.4.1. U.S.: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.3.5. Muscle Relaxant Drugs Market - Canada
      • 8.3.5.1. Canada: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.4. Muscle Relaxant Drugs Market - Europe
    • 8.4.1. Europe: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.4. Muscle Relaxant Drugs Market - UK
      • 8.4.4.1. UK: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.5. Muscle Relaxant Drugs Market - France
      • 8.4.5.1. France: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.6. Muscle Relaxant Drugs Market - Germany
      • 8.4.6.1. Germany: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.7. Muscle Relaxant Drugs Market - Italy
      • 8.4.7.1. Italy: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.8. Muscle Relaxant Drugs Market - Spain
      • 8.4.8.1. Spain: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.9. Muscle Relaxant Drugs Market - Netherlands
      • 8.4.9.1. Netherlands: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.10. Muscle Relaxant Drugs Market - Russia
      • 8.4.10.1. Russia: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.5. Muscle Relaxant Drugs Market - Asia Pacific
    • 8.5.1. Asia Pacific: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.4. Muscle Relaxant Drugs Market - China
      • 8.5.4.1. China: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.5. Muscle Relaxant Drugs Market - India
      • 8.5.5.1. India: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.6. Muscle Relaxant Drugs Market - Malaysia
      • 8.5.6.1. Malaysia: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.7. Muscle Relaxant Drugs Market - Japan
      • 8.5.7.1. Japan: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.8. Muscle Relaxant Drugs Market - Indonesia
      • 8.5.8.1. Indonesia: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.9. Muscle Relaxant Drugs Market - South Korea
      • 8.5.9.1. South Korea: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.6. Muscle Relaxant Drugs Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.4. Muscle Relaxant Drugs Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.5. Muscle Relaxant Drugs Market - UAE
      • 8.6.5.1. UAE: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.6. Muscle Relaxant Drugs Market - Israel
      • 8.6.6.1. Israel: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.7. Muscle Relaxant Drugs Market - South Africa
      • 8.6.7.1. South Africa: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 8.7. Muscle Relaxant Drugs Market - Latin America
    • 8.7.1. Latin America: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.4. Muscle Relaxant Drugs Market - Mexico
      • 8.7.4.1. Mexico: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.5. Muscle Relaxant Drugs Market - Brazil
      • 8.7.5.1. Brazil: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.6. Muscle Relaxant Drugs Market - Argentina
      • 8.7.6.1. Argentina: Muscle Relaxant Drugs Market, by Drug Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Muscle Relaxant Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Muscle Relaxant Drugs Market, by Route of Administration, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Amneal Pharmaceuticals
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Drug Type Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Ipsen Biopharmaceuticals
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Drug Type Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Merz Pharmaceuticals
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Drug Type Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Par Pharmaceutical
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Drug Type Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Endo Pharmaceuticals
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Drug Type Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Vertical Pharmaceuticals
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Drug Type Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Mallinckrodt
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Drug Type Benchmarking
    • 10.7.4. Recent Development
  • 10.8. SteriMax
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Drug Type Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Eisai Co.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Drug Type Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Metacel Pharmaceuticals
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Drug Type Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Metacel Pharmaceuticals
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Drug Type Benchmarking
    • 10.11.4. Recent Development